News & Views

News and updates from our areas of work

WHO Pre-Qualification of Maternal Health Supplies

16 août 2016 | Under News | Posted by

Maternal mortality remains a major challenge for the global health community. Pregnancy and childbirth sadly too often result in danger to the mother or newborn in many countries around the world. Pre-eclampsia and eclampsia are high among the risks faced by pregnant women, responsible for up to 15% of maternal deaths worldwide each year.

And yet many maternal deaths could be relatively easy prevented with widely available and relatively affordable medicines. For example, magnesium sulfate is recognised as an essential medicine on the WHO Essential Medicines List (EML) and on many national EMLs. Its benefits have been recognised and prioritised among the UN Commission’s list of lifesaving commodities.

Important maternal and reproductive health products have just been added to the WHO list of Pre-Qualified Medicines, including:

- Magnesium sulfate heptahydrate, 500mg/ml, Injection; Inresa Arzneimittel GmbH
- Ceftriaxone (as sodium), 1g, Powder for injection; Sinopharm Zhijun (Shenzhen) Pharmaceutical Co Ltd
- Mifepristone, 200mg, Tablets; China Resources Zizhu Pharmaceutical Co Ltd
- Levonorgestrel, 30µg, Tablets; Jai Pharma Limited

For further details of the list of WHO Pre-Qualified medicines and the WHO Pre-Qualification process, please see the WHO PQ website. Queries may be addressed directly to the WHO Pre-Qualification team at prequal@who.int.